Angelo Palmese, Head of Characterization and Innovative Analytics at Merck, explains why Merck chose to implement attribute monitoring strategies for drug development and QC with BioAccord.
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
0:00
Stream Type LIVE
Remaining Time -0:00
1x
2x
1.75x
1.5x
1.25x
1x, selected
0.75x
0.5x
Chapters
descriptions off, selected
captions settings, opens captions settings dialog
captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Angelo Palmese, Head of Characterization and Innovative Analytics at Merck, explains why Merck chose to implement attribute monitoring strategies for drug development and QC with BioAccord.